Product Pipeline
Xenon is focused on advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression
Our lead molecule, azetukalner (XEN1101), is a novel, potent Kv7 potassium channel opener being developed for the treatment of epilepsy, major depressive disorder, and potentially other neurological disorders.
Our pre-clinical work leverages our deep ion channel expertise to develop promising drug candidates that target sodium and potassium channels.
